Nanexa AB (publ) (STO:NANEXA)

Market Cap	356.97M
Revenue (ttm)	38.40M
Net Income (ttm)	-30.96M
Shares Out	156.91M
EPS (ttm)	-0.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	520,001
Average Volume	460,470
Open	2.305
Previous Close	2.310
Day's Range	2.265 - 2.350
52-Week Range	0.701 - 3.150
Beta	1.80
RSI	55.64
Earnings Date	Aug 27, 2025

About Nanexa AB

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, rest of Europe, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a depot drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 13
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: NANEXA

Financial Performance

In 2024, Nanexa AB's revenue was 46.69 million, a decrease of -21.07% compared to the previous year's 59.16 million. Losses were -24.91 million, -67.40% less than in 2023.